Literature DB >> 19214988

UCH-L1 expression of podocytes in diseased glomeruli and in vitro.

Yuan Liu1, Jiajing Wu, Huijuan Wu, Tianzhan Wang, Hualei Gan, Xin Zhang, Ye Liu, Ruixi Li, Zhonghua Zhao, Qi Chen, Muyi Guo, Zhigang Zhang.   

Abstract

Ubiquitin C-terminal hydrolase-L1 (UCH-L1), an important member of de-ubiquitination enzyme families involved in the ubiquitin-proteasome pathway, is expressed mainly in neural and reproductive systems as well as in some tumours. Recently, expression of UCH-L1 has been discovered in parietal epithelial cells of Bowman's capsules and some tubular epithelia in the kidney. However, whether UCH-L1 is expressed in the capillary tufts of the glomeruli has not yet become clear. In this study, we used immunohistochemistry, double immunofluorescence labelling, immunoelectron microscopy in kidney biopsy tissues and western blot in cultured rat podocytes to investigate the expression of UCH-L1 and the regulation of this expression in podocytes. The results demonstrated that UCH-L1 was expressed in podocytes and its expression was significantly higher in acute proliferative glomerulonephritis (APGN), lupus nephritis (LN), membranous glomerulonephritis (MGN) and IgA nephropathy than that in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), minor abnormality and normal kidney tissues (p < 0.05). In in vitro experiments, western blot showed that UCH-L1 expression significantly increased in the two groups of podocytes co-cultured with mesangial cells exposed to ATS 50 microl/ml and ATS 50 microl/ml with normal human serum 30 microl/ml, respectively (p < 0.05), while the other groups treated with TGFbeta1 1 ng/ml, TNFalpha 10 ng/ml or IL-1 10 ng/ml had little rise of UCH-L1 expression, with no statistical significance compared with normal control (p > 0.05). Further tests indicated that the percentage of PCNA-positive podocytes in LN, APGN and IgA nephropathy was significantly higher than that in MCD, FSGS and normal control (p < 0.05). These data show for the first time that podocytes do express UCH-L1 and that its expression can be increased in these immunocomplex-mediated nephrites. The immune injury is a main cause for stimulating podocytes to express UCH-L1. The expression of UCH-L1 may be associated with the regeneration of podocytes as a repair response to immunocomplex-mediated injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19214988     DOI: 10.1002/path.2511

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

1.  A Uchl1-Histone2BmCherry:GFP-gpi BAC transgene for imaging neuronal progenitors.

Authors:  Carrie B Wiese; Nicole Fleming; Dennis P Buehler; E Michelle Southard-Smith
Journal:  Genesis       Date:  2013-10-21       Impact factor: 2.487

2.  Cell cycle re-entry sensitizes podocytes to injury induced death.

Authors:  Manuel Hagen; Eva Pfister; Andrea Kosel; Stuart Shankland; Jeffrey Pippin; Kerstin Amann; Christoph Daniel
Journal:  Cell Cycle       Date:  2016-05-27       Impact factor: 4.534

3.  Role of A20/TNFAIP3 deficiency in lupus nephritis in MRL/lpr mice.

Authors:  Ling Sun; Lu-Xi Zou; Yu-Chen Han; Dong-Dong Zhu; Ting Chen; Jie Wang
Journal:  Clin Exp Nephrol       Date:  2019-12-07       Impact factor: 2.801

Review 4.  UCH-L1 Expressed by Podocytes: a Potentially Therapeutic Target for Lupus Nephritis?

Authors:  Ji-Hong Cui; Xin Xie
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

5.  Alterations in the ubiquitin proteasome system in persistent but not reversible proteinuric diseases.

Authors:  Maire Beeken; Maja T Lindenmeyer; Simone M Blattner; Victoria Radón; Jun Oh; Tobias N Meyer; Diana Hildebrand; Hartmut Schlüter; Anna T Reinicke; Jan-Hendrik Knop; Anuradha Vivekanandan-Giri; Silvia Münster; Marlies Sachs; Thorsten Wiech; Subramaniam Pennathur; Clemens D Cohen; Matthias Kretzler; Rolf A K Stahl; Catherine Meyer-Schwesinger
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

6.  DC-SIGN expression on podocytes and its role in inflammatory immune response of lupus nephritis.

Authors:  Minchao Cai; Tong Zhou; Xuan Wang; Minghua Shang; Yueyue Zhang; Maocai Luo; Chundi Xu; Weijie Yuan
Journal:  Clin Exp Immunol       Date:  2015-11-24       Impact factor: 4.330

Review 7.  Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.

Authors:  Naeemeh Khalesi; Shahla Korani; Mitra Korani; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Inflammopharmacology       Date:  2021-08-23       Impact factor: 4.473

8.  The expression and significance of neuronal iconic proteins in podocytes.

Authors:  Yu Sun; Hongxia Zhang; Ruimin Hu; Jianyong Sun; Xing Mao; Zhonghua Zhao; Qi Chen; Zhigang Zhang
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

9.  Wnt/β-Catenin Signaling Mediated-UCH-L1 Expression in Podocytes of Diabetic Nephropathy.

Authors:  Hongxia Zhang; Weili Luo; Yonghong Sun; Yanchun Qiao; Liying Zhang; Zhilian Zhao; Shijun Lv
Journal:  Int J Mol Sci       Date:  2016-08-25       Impact factor: 5.923

10.  IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients.

Authors:  Josephe A Honorat; Lars Komorowski; Keith A Josephs; Kai Fechner; Erik K St Louis; Shannon R Hinson; Sabine Lederer; Neeraj Kumar; Avi Gadoth; Vanda A Lennon; Sean J Pittock; Andrew McKeon
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.